Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics adds Merck oncology executive Marjorie Green to its board of directors

Neutral Impact 2 of 5 leadership Written later

NeoGenomics expanded its board from nine to ten members on June 19, 2025, and appointed Marjorie C. Green to fill the new seat. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. The filing reports no financial results or changes to guidance, so the appointment is the only shareholder-relevant event disclosed.

Key points

  • Board size increased from nine to ten members; Green appointed June 19, 2025
  • Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck
  • Previously held roles at Seagen and Genentech, per the press release
  • Will serve until the 2026 annual meeting of stockholders or earlier resignation or removal

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECJun 24, 2025, 7:10 AM ET
Accession number0001077183-25-000145

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 24, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.